💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

EU drug agency head fears loss of expert staff after Brexit

Published 11/15/2016, 02:08 PM
Updated 11/15/2016, 02:10 PM
© Reuters. Guido Rasi, executive director the European Medicines Agency (EMA) poses for a portrait at his office in London

LONDON (Reuters) - The head of Europe's drugs regulator is braced for disruption following Britain's vote to leave the European Union (EU) and said he feared losing expert staff if, as widely expected, the regulator is forced to decamp from London.

The European Medicines Agency (EMA) approves treatments for all EU countries from its headquarters among global banks in London's Canary Wharf. It is the largest EU body in Britain.

"My concern is to lose experts, to lose staff," Executive Director Guido Rasi told an industry conference on Tuesday.

Most industry watchers believe Britain's decision to leave the EU will mean Europe's equivalent of the U.S. Food and Drug Administration is forced to move to a city within the EU, although there has been no official announcement on this.

EU countries including Spain, France, Poland, Italy, Sweden, Denmark and Ireland have already offered to host the EMA instead of Britain and the tussle over its future location is expected to form part of complex political horse-trading.

The European Banking Authority is also based in London.

"I'm flattered that so many different nations want us but my concern is workability," Rasi told the Pharma Integrates conference.

The EMA employs nearly 900 people, many of whom have made a long-term home in London, since the agency has been based here for the past two decades, he said.

Losing Britain could also leave a big hole in the EMA's scientific capability, since British experts are among the biggest contributors to its drug assessment system.

Rasi said the EMA had set up a task force to address the challenges arising following the Brexit vote but noted that the decision on if and when the agency would move was up to European politicians.

Irish Health Minister Simon Harris, announcing Dublin as a candidate to house the EMA last month, said it appeared inevitable that the EMA would have to relocate from London to another EU member state.

© Reuters. Guido Rasi, executive director the European Medicines Agency (EMA) poses for a portrait at his office in London

Housing the industry regulator is viewed as a valuable prize for European cities, since it will lead to an injection of a skilled workforce and potentially attract companies.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.